Margarett Shnorhavorian1,2, David R Doody2, Vivien W Chen3, Ann S Hamilton4, Ikuko Kato5, Rosemary D Cress6, Michele West7, Xiao-Cheng Wu3, Theresa H M Keegan8, Linda C Harlan9, Stephen M Schwartz2,10. 1. Department of Urology, Division of Pediatric Urology, University of Washington, Seattle Children's Hospital. 2. Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, WA. 3. Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA. 4. Keck School of Medicine, University of Southern California, Los Angeles. 5. Departments of Oncology and Pathology, School of Medicine, Wayne State University, Detroit, MI. 6. Department of Public Health Sciences, School of Medicine, University of California, Davis, Davis, CA. 7. Department of Epidemiology, University of Iowa, Iowa City, IA. 8. Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, University of California, Davis, Sacramento, CA. 9. Applied Research Program, National Cancer Institute, Bethesda, MD. 10. Department of Epidemiology, University of Washington.
Abstract
PURPOSE OF THE STUDY: Adolescent and young adult (AYA) cancer patients are underrepresented in clinical trials, but the reasons for this phenomenon are unknown. PATIENTS AND METHODS: Questionnaire and medical record data from 515 AYA cancer patients (21 acute lymphocytic leukemia [ALL], 201 germ cell tumor, 141 Hodgkin lymphoma, 128 non-Hodgkin lymphoma, 24 sarcoma) from a population-based study were analyzed. We used multivariable models to determine characteristics associated with patient knowledge of the availability of clinical trials for their cancer. Reasons for not participating in a trial were tabulated. RESULTS: In total, 63% of patients reported not knowing whether a relevant clinical trial was available, 20% reported knowing that a clinical trial was not available, and 17% reported that a trial was available. Among patients reporting an available trial, 67% were recommended for enrollment. Knowing about the availability of clinical trials was associated with having ALL (odds ratio=2.9, 95% confidence interval=1.1, 7.8). Reporting that a clinical trial was available was positively associated with having ALL, Hodgkin lymphoma, non-Hodgkin lymphoma and sarcoma (relative to germ cell tumor) and working full-time or in school full-time (odds ratio=2.6, 95% confidence interval=1.0, 6.7). Concerns about involvement in research (57%) and problems accessing trials (21%) were the primary reasons cited for not enrolling among patients who knew that a trial was available. CONCLUSIONS: Improvement in AYA cancer patient clinical trial enrollment will require enhancing knowledge about trial availability and addressing this population's concerns about participating in medical research.
PURPOSE OF THE STUDY: Adolescent and young adult (AYA) cancer patients are underrepresented in clinical trials, but the reasons for this phenomenon are unknown. PATIENTS AND METHODS: Questionnaire and medical record data from 515 AYA cancer patients (21 acute lymphocytic leukemia [ALL], 201 germ cell tumor, 141 Hodgkin lymphoma, 128 non-Hodgkin lymphoma, 24 sarcoma) from a population-based study were analyzed. We used multivariable models to determine characteristics associated with patient knowledge of the availability of clinical trials for their cancer. Reasons for not participating in a trial were tabulated. RESULTS: In total, 63% of patients reported not knowing whether a relevant clinical trial was available, 20% reported knowing that a clinical trial was not available, and 17% reported that a trial was available. Among patients reporting an available trial, 67% were recommended for enrollment. Knowing about the availability of clinical trials was associated with having ALL (odds ratio=2.9, 95% confidence interval=1.1, 7.8). Reporting that a clinical trial was available was positively associated with having ALL, Hodgkin lymphoma, non-Hodgkin lymphoma and sarcoma (relative to germ cell tumor) and working full-time or in school full-time (odds ratio=2.6, 95% confidence interval=1.0, 6.7). Concerns about involvement in research (57%) and problems accessing trials (21%) were the primary reasons cited for not enrolling among patients who knew that a trial was available. CONCLUSIONS: Improvement in AYA cancer patient clinical trial enrollment will require enhancing knowledge about trial availability and addressing this population's concerns about participating in medical research.
Authors: Helen M Parsons; Linda C Harlan; Nita L Seibel; Jennifer L Stevens; Theresa H M Keegan Journal: J Clin Oncol Date: 2011-09-19 Impact factor: 44.544
Authors: C Catania; D Radice; G Spitaleri; L Adamoli; C Noberasco; A Delmonte; F Vecchio; F de Braud; F Toffalorio; A Goldhirsch; T De Pas Journal: Psychooncology Date: 2013-10-10 Impact factor: 3.894
Authors: Margaret M Byrne; Stacey L Tannenbaum; Stefan Glück; Judith Hurley; Michael Antoni Journal: Med Decis Making Date: 2013-07-29 Impact factor: 2.583
Authors: Linda C Harlan; Charles F Lynch; Theresa H M Keegan; Ann S Hamilton; Xiao-Cheng Wu; Ikuko Kato; Michele M West; Rosemary D Cress; Stephen M Schwartz; Ashley W Smith; Dennis Deapen; Sonja M Stringer; Arnold L Potosky Journal: J Cancer Surviv Date: 2011-01-28 Impact factor: 4.442
Authors: Chelsea Anderson; Andrew B Smitherman; Clare Meernik; Teresa P Edwards; Allison M Deal; Nancy Cannizzaro; Christopher D Baggett; Chun Chao; Hazel B Nichols Journal: J Adolesc Young Adult Oncol Date: 2019-09-23 Impact factor: 2.223
Authors: Ashley Wilder Smith; Theresa Keegan; Ann Hamilton; Charles Lynch; Xiao-Cheng Wu; Stephen M Schwartz; Ikuko Kato; Rosemary Cress; Linda Harlan Journal: Pediatr Blood Cancer Date: 2018-10-07 Impact factor: 3.167
Authors: Victoria Forcina; Branavan Vakeesan; Chelsea Paulo; Laura Mitchell; Jennifer Ah Bell; Seline Tam; Kate Wang; Abha A Gupta; Jeremy Lewin Journal: Adolesc Health Med Ther Date: 2018-06-13
Authors: Carla Vlooswijk; Lonneke V van de Poll-Franse; Silvie H M Janssen; Esther Derksen; Milou J P Reuvers; Rhodé Bijlsma; Suzanne E J Kaal; Jan Martijn Kerst; Jacqueline M Tromp; Monique E M M Bos; Tom van der Hulle; Roy I Lalisang; Janine Nuver; Mathilde C M Kouwenhoven; Winette T A van der Graaf; Olga Husson Journal: Curr Oncol Date: 2022-07-29 Impact factor: 3.109
Authors: Pandora Patterson; Kimberley R Allison; Helen Bibby; Kate Thompson; Jeremy Lewin; Taia Briggs; Rick Walker; Michael Osborn; Meg Plaster; Allan Hayward; Roslyn Henney; Shannyn George; Dominic Keuskamp; Antoinette Anazodo Journal: Cancers (Basel) Date: 2021-05-28 Impact factor: 6.639
Authors: Helen M Parsons; Dolly C Penn; Qian Li; Rosemary D Cress; Brad H Pollock; Marcio H Malogolowkin; Ted Wun; Theresa H M Keegan Journal: Pediatr Blood Cancer Date: 2018-09-06 Impact factor: 3.838
Authors: Radhika Sreeraman Kumar; Ram Thapa; Youngchul Kim; Nikhil I Khushalani; Vernon K Sondak; Damon R Reed Journal: Cancer Med Date: 2018-02-25 Impact factor: 4.452
Authors: Belle H de Rooij; Nicole P M Ezendam; Floortje Mols; Pauline A J Vissers; Melissa S Y Thong; Carla C P Vlooswijk; Simone Oerlemans; Olga Husson; Nicole J E Horevoorts; Lonneke V van de Poll-Franse Journal: Qual Life Res Date: 2018-08-30 Impact factor: 4.147